QIAGEN N.V. (QGEN) recently announced the launch of 100 new assays for its digital polymerase chain reaction (dPCR) platform — QIAcuity. The assays will be used to study cancer, inherited genetic disorders, infectious disease surveillance, and food and environmental monitoring. These are available through QIAGEN's comprehensive GeneGlobe platform. The latest launch will be an addition to the company's PCR product portfolio. QGEN's Likely Stock Trend Following the News Shares of QGEN were up 0.04% in pre-mar ...